Go online to PeerView.com/TKZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. With new developments in the advanced renal cell carcinoma (RCC) treatment landscape, clinicians have more opportunities for personalizing therapeutic approaches for patients with RCC. Validation of novel combinatorial approaches, such as dual checkpoint inhibition and immunotherapy plus targeted agents, have led to FDA approvals, and novel approaches synergistically combining checkpoint inhibition with targeted therapy have expanded frontline treatment options for patients with advanced disease. This program features the latest research on the efficacy and safety of these newer treatment approaches and expert guidance on selecting and managing the overlapping and non-overlapping adverse events associated with potent immune-based and targeted therapy treatment options. Upon completion of this activity, participants sould be better able to: Identify the latest efficacy and safety findings on new treatment approaches, such as immune checkpoint inhibitors, targeted tyrosine kinase inhibitors, and novel and emerging combination approaches, for advanced and/or resectable renal cell carcinoma (RCC), Choose appropriate, personalized treatment regimens that make use of immune and targeted therapies for patients with advanced RCC in the first-line setting based on pertinent patient- and disease-related characteristics, Integrate novel components into treatment plans over multiple lines of therapy for patients with previously-treated advanced RCC taking into account patient treatment history and comorbidities, Assess treatment-related adverse events in patients with RCC receiving immunotherapy and targeted agents.